Clinical Considerations: New Anti-Inflammatories & New CFTR Modulators

Volume 8, Issue 13

Clinical Considerations: New Anti-Inflammatories & New CFTR Modulators

In this issue:

New CFTR modulators for F508del mutations? New research into reducing inflammation in the CF lung? In this issue, Dr. Jennifer Taylor-Cousar from National Jewish Health in Denver explains the potential clinical impact of new and emerging CF disease modifying therapies.

Learning objectives:

Identify appropriate patients for the initiation of disease modifying anti-inflammatory therapy.
Summarize the potential benefits and risks, as reported in phase 2 studies, of triple combination CFTR modulator therapy.

Author:

Jennifer Taylor-Cousar, MD, MSCS

Medical Director, Clinical Research Services
Co-Director and CF TDC Director, Adult CF Program
Interim Associate Vice President of Diversity, Equity and Inclusion
Professor, Departments of Internal Medicine and Pediatrics
Divisions of Pulmonary, Critical Care and Sleep Medicine and Pediatric Pulmonary Medicine
National Jewish Health
Denver, CO

Guest Faculty Disclosures

Dr. Taylor Cousar has indicated she will not be referencing the unlabeled or unapproved use of any drugs or products relevant to today’s discussion, with the exception of the new agents in phase 2/phase 3 trials that form the basis of this presentation.

Unlabeled/Unapproved Uses

Dr. Taylor-Cousar has indicated that, as faculty at an institution that is part of the CF TDN, she has been a site PI on studies for Bayer, Celtaxys, Proteostasis, and Vertex Pharmaceuticals Incorporated. She has also received consulting fees from Gilead Sciences, Inc and Santhera. She has done clinical trial consulting and/or advisory boards for Gilead Sciences, Inc., Proteostasis, Protalix, Santhera, and Vertex Pharmaceuticals Incorporated. She has received grant funding from Gilead Sciences, Inc.

Program Directors:

Peter J. Mogayzel, Jr., MD, PhD

Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University School of Medicine
Baltimore, MD

Noah Lechtzin, MD, MHA

Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Suzanne Sullivan, RN, BSN

Senior Clinical Nurse
The Johns Hopkins University
Baltimore, MD

Guest Faculty Disclosures:

Unlabeled/Unapproved Uses:

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: September 27, 2019
Expiration date: September 26, 2021

Start Issue